H.C. Wainwright analyst Robert Burns reiterated a Hold rating on Neon Therapeutics (NTGN) yesterday. The company’s shares closed last Monday at $1.76, close to its 52-week low of $0.88.
Neon Therapeutics has an analyst consensus of Hold, with a price target consensus of $8.40, representing a 380.0% upside. In a report issued on January 16, Robert W. Baird also downgraded the stock to Hold with a $2.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.51 and a one-year low of $0.88. Currently, Neon Therapeutics has an average volume of 306K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials.
